Nabriva Therapeutics (NASDAQ:NBRV) Stock Price Up 7.8%

Share on StockTwits

Nabriva Therapeutics PLC – (NASDAQ:NBRV) rose 7.8% during trading on Tuesday . The stock traded as high as $1.39 and last traded at $1.39, approximately 2,014,500 shares traded hands during trading. An increase of 25% from the average daily volume of 1,607,335 shares. The stock had previously closed at $1.29.

NBRV has been the subject of several analyst reports. Needham & Company LLC reiterated a “buy” rating on shares of Nabriva Therapeutics in a report on Wednesday, November 13th. ValuEngine upgraded shares of Nabriva Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday, January 4th. BidaskClub cut shares of Nabriva Therapeutics from a “sell” rating to a “strong sell” rating in a report on Tuesday, December 24th. Finally, Wedbush reiterated an “outperform” rating and set a $7.00 price target on shares of Nabriva Therapeutics in a report on Friday, November 15th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and six have issued a buy rating to the stock. Nabriva Therapeutics currently has an average rating of “Buy” and a consensus target price of $6.79.

The firm’s fifty day moving average price is $1.57 and its 200-day moving average price is $1.99. The company has a current ratio of 5.81, a quick ratio of 5.79 and a debt-to-equity ratio of 0.87. The firm has a market cap of $1.21 billion, a price-to-earnings ratio of -0.85 and a beta of 2.31.

Nabriva Therapeutics (NASDAQ:NBRV) last issued its earnings results on Tuesday, November 12th. The biotechnology company reported ($0.24) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.28) by $0.04. Nabriva Therapeutics had a negative net margin of 910.45% and a negative return on equity of 171.36%. The business had revenue of $6.92 million during the quarter, compared to analysts’ expectations of $1.23 million. On average, sell-side analysts expect that Nabriva Therapeutics PLC – will post -1.14 earnings per share for the current year.

Several institutional investors have recently modified their holdings of NBRV. Sterling Investment Advisors Ltd. boosted its holdings in shares of Nabriva Therapeutics by 100.0% in the 3rd quarter. Sterling Investment Advisors Ltd. now owns 20,000 shares of the biotechnology company’s stock valued at $40,000 after buying an additional 10,000 shares in the last quarter. Woodard & Co. Asset Management Group Inc. ADV acquired a new position in shares of Nabriva Therapeutics in the 3rd quarter valued at $40,000. State Street Corp acquired a new position in shares of Nabriva Therapeutics in the 3rd quarter valued at $65,000. Barclays PLC boosted its holdings in shares of Nabriva Therapeutics by 171,923.1% in the 3rd quarter. Barclays PLC now owns 44,726 shares of the biotechnology company’s stock valued at $89,000 after buying an additional 44,700 shares in the last quarter. Finally, A.R.T. Advisors LLC acquired a new position in shares of Nabriva Therapeutics in the 2nd quarter valued at $90,000. Institutional investors and hedge funds own 2.75% of the company’s stock.

Nabriva Therapeutics Company Profile (NASDAQ:NBRV)

Nabriva Therapeutics plc, a clinical stage biopharmaceutical company, engages in the research and development of anti-infective agents to treat infections in humans. The company focuses on the pleuromutilin class of antibiotics. Its lead product candidate is lefamulin, which is in Phase III clinical trials in intravenous and oral formulations for the treatment of community-acquired bacterial pneumonia; and has completed Phase II clinical trials for the treatment of acute bacterial skin and skin structure infection.

Further Reading: Why are gap-down stocks important?

Receive News & Ratings for Nabriva Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.